Press Releases - News for BioHouston

The top 50 press releases in our database are displayed below.

26 Record(s) Found. Displaying Page 1:

Amarantus BioSciences Licenses Parkinson’s Disease Diagnostic Biomarker Test from Power3 Medical Products
Release Date: 23-Jan-12 Author or Contact: Remy Bernarda
SUNNYVALE, CA and THE WOODLANDS, TX - January 23, 2012- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein being developed for the treatment of Parkinson's Disease, today announced an exclusive worldwide license agreement with Power3 Medical Products, Inc. (OTCBB: PWRM) for the NuroPro® Blood Test as it relates to Parkinson's disease diagnosis. ...
Click to read Amarantus BioSciences Licenses Parkinson’s Disease Diagnostic Biomarker Test from Power3 Medical Products

Pernix Therapeutics Announces Agreement to License a New FDA-Approved Product to Treat Gastroenterology Disease
Release Date: 23-Jan-12 Author or Contact: Joseph Schepers
THE WOODLANDS, Texas--(BUSINESS WIRE)-- Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced it has entered into a license and supply agreement with a private company for a new FDA-approved prescription product to treat gastroenterology disease. Under the terms of the agreement, Pernix obtained exclusive marketing ...
Click to read Pernix Therapeutics Announces Agreement to License a New FDA-Approved Product to Treat Gastroenterology Disease

LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
Release Date: 9-Jan-12 Author or Contact: D. Wade Walke, Ph.D.
Combination of LX4211 and DPP-4 Inhibitor Reduces Blood Sugar After Meals and Increases GLP-1 in Type 2 Diabetic Patients More than DPP-4 Inhibitor Alone The Woodlands, Texas, January 9, 2012 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today top-line results from the first clinical study testing the combined effects of LX4211, a novel sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, with the dipeptidyl ...
Click to read LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes

Cyberonics Announces FDA Approval of Re-Designed AspireHC™ Generator for VNS Therapy
Release Date: 3-Jan-12 Author or Contact: Greg Browne
HOUSTON, Jan. 3, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that the United States Food and Drug Administration(FDA) has approved its re-designed AspireHC (High Capacity) generator, which was the subject of a voluntary product withdrawal in August 2011. "We are pleased that the FDA was able to complete its review in approximately 60 days, enabling us to resume our limited commercial release of the AspireHC ...
Click to read Cyberonics Announces FDA Approval of Re-Designed AspireHC™ Generator for VNS Therapy

New Biotech Cluster in the U.S. Are Scrambling to Challenge Established Regions
Release Date: 3-Jan-12 Author or Contact:
Jan. 3, 2012 -- The weak economy of the past four years combined with cutbacks due to mergers and acquisitions have helped consolidate U.S. biopharma activity further within the nation's largest life sciences clusters. Yet that has not stopped several other U.S. regions from trying to carve out their own piece of the life science pie. The real estate firm Jones Lang LaSalle (JLL) highlighted nine examples of what it called emerging ...
Click to read New Biotech Cluster in the U.S. Are Scrambling to Challenge Established Regions

Lonza Launches Novel Plasmid (pDNA) Production Platform for Microbial Derived Biopharmaceuticals
Release Date: 20-Dec-11 Author or Contact: Melanie Disa
•The new pDNA platform results in reduced development time, higher product yields, improved purity and shorter processing time •The process is compatible with a variety of E.coli hosts, providing the flexibility of using either a client's strain or a Lonza developed strain •The microbial-based platform is available for process development projects in either Lonza's Hopkinton, MA (USA) or ...
Click to read Lonza Launches Novel Plasmid (pDNA) Production Platform for Microbial Derived Biopharmaceuticals

Abbott pays out $400 million for access to more Reata compounds
Release Date: 12-Dec-11 Author or Contact: Ken Grogan
Abbott Laboratories has signed another deal with partner Reata Pharmaceuticals which will boost the latter's bank balance by a further $400 million. The companies will jointly develop Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs). The agreement is in addition to the partnership they announced in September 2010 in which Abbott paid some $450 million to get certain rights to ...
Click to read Abbott pays out $400 million for access to more Reata compounds

Opexa Announces Publication in Multiple Sclerosis Journal of Tovaxin® Phase IIb Clinical Trial Results
Release Date: 14-Nov-11 Author or Contact: Neil Warma
THE WOODLANDS, Texas (November 14, 2011) - Opexa Therapeutics, Inc. (NASDAQ: OPXA), developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that results of the Company's prior Phase IIb clinical trial of Tovaxin have been published in a leading peer-reviewed publication, Multiple Sclerosis Journal. The Phase IIb placebo-controlled study [Tovaxin for Early ...
Click to read Opexa Announces Publication in Multiple Sclerosis Journal of Tovaxin® Phase IIb Clinical Trial Results

Lexicon Announces Plans for Rights Offering to Stockholders
Release Date: 11-Nov-11 Author or Contact: D. Wade Walke, Ph.D.
THE WOODLANDS, Texas, Nov. 11, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans for a rights offering pursuant to an effective shelf registration statement in which its stockholders will receive non-transferable subscription rights to purchase up to 144,247,800 shares of its common stock in the aggregate. In the rights offering, stockholders will receive one non-transferable subscription right ...
Click to read Lexicon Announces Plans for Rights Offering to Stockholders

Mystic Pharmaceuticals Receives U.S. Patent for Innovative Unit Dose Packaging and Delivery Technology for Drugs and Biologics
Release Date: 9-Nov-11 Author or Contact: Melissa Brandt
AUSTIN, TX - November 9, 2011 (Business Wire) -- Mystic Pharmaceuticals, Inc. announces today that it has been granted U.S. Patent No. 8,047,204, "Combination Unit Dose Dispensing Containers I" for a novel unit dose blister packaging technology. This packaging technology is a key element of the company's VersiDoserTM and VRx2TM drug and biologic delivery systems. Mystic's delivery platforms provide preservative free unit dose packaging and ...
Click to read Mystic Pharmaceuticals Receives U.S. Patent for Innovative Unit Dose Packaging and Delivery Technology for Drugs and Biologics

Opexa’s Tovaxin® for the Treatment of Multiple Sclerosis Granted Fast Track Designation by FDA
Release Date: 8-Nov-11 Author or Contact: Neil Warma
THE WOODLANDS, Texas--(November 8, 2011)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), announced today that its lead drug candidate Tovaxin® has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Secondary Progressive Multiple Sclerosis (SPMS). The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs intended to treat ...
Click to read Opexa’s Tovaxin® for the Treatment of Multiple Sclerosis Granted Fast Track Designation by FDA

Lonza Viral's Production Capacity Expansion: Update
Release Date: 2-Nov-11 Author or Contact: Xin Swanson
Lonza's Viral-based Therapeutics business is pleased to update you on the status of our new GMP clean suite. We continue to remain on target for completion of construction and validation of this suite by end of Q1 2012. Notably, we recently held our Type C meeting with FDA. This meeting was to review the new suite's design with regards to personnel, materials and air flow, cleaning protocols, and other critical components of ...
Click to read Lonza Viral's Production Capacity Expansion: Update

Opexa Elects Gail Maderis to Board of Directors
Release Date: 2-Nov-11 Author or Contact: Neil Warma
Industry Expert Brings Significant Expertise to Tovaxin® Clinical Development Program THE WOODLANDS, TX (November 2, 2011) - Opexa Therapeutics, Inc. (NASDAQ: OPXA) today announced the election of Gail J. Maderis to its Board of Directors at its annual meeting of shareholders held on October 27, 2011. Ms. Maderis will Chair the Board's nominating and corporate governance committee, as well as serve on the Board's compensation ...
Click to read Opexa Elects Gail Maderis to Board of Directors

Opexa Elects Gail Maderis to Board of Directors
Release Date: 2-Nov-11 Author or Contact: Neil Warma
Industry Expert Brings Significant Expertise to Tovaxin® Clinical Development Program THE WOODLANDS, TX (November 2, 2011) - Opexa Therapeutics, Inc. (NASDAQ: OPXA) today announced the election of Gail J. Maderis to its Board of Directors at its annual meeting of shareholders held on October 27, 2011. Ms. Maderis will Chair the Board's nominating and corporate governance committee, as well as serve on the Board's compensation ...
Click to read Opexa Elects Gail Maderis to Board of Directors

Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer
Release Date: 27-Oct-11 Author or Contact: Brandi Floberg
PASADENA, Calif. - October 27, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has appointed Bruce Given, M.D. to the position of Chief Operating Officer of the Company effective October 26, 2011. Since February 1, 2010, Dr. Given has served as Chief Executive Officer of Leonardo Biosystems, Inc., a company in which Arrowhead maintains a minority equity interest, and he also has served as a director of Calando ...
Click to read Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer

Cormedics Completes Pre-Submission Financing & Signs Development Agreement With J&J Unit
Release Date: 19-Sep-11 Author or Contact:
HOUSTON, September 19, 2011 - Cormedics Corp. has received new financing to support refinement of the company's intrapericardial access device for its submission to the Food and Drug Administration, and has signed a development agreement with a Johnson & Johnson affiliate company, Biosense Webster. The new investment, by Palo Alto medical technology investor Patrick Rivelli, is in addition to ...
Click to read Cormedics Completes Pre-Submission Financing & Signs Development Agreement With J&J Unit

Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
Release Date: 13-Sep-11 Author or Contact: D. Wade Walke
THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company is presenting clinical data this week at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal. Data from the mechanistic study being presented at the EASD meeting ...
Click to read Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting

LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Release Date: 13-Sep-11 Author or Contact: D. Wade Walke
THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2 (SGLT1 and SGLT2). The favorable safety profile and effects on multiple parameters of ...
Click to read LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects

Dr. Mark Freedman to Join Opexa’s Scientific Advisory Board
Release Date: 12-Sep-11 Author or Contact: Neil K. Warma
THE WOODLANDS, Texas (September 12, 2011) - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced it has recently added a key international opinion leader to its Scientific Advisory Board. Mark Freedman, M.D., is a professor of medicine in the field of neurology at the University of Ottawa, and director of the Multiple Sclerosis Research Unit at ...
Click to read Dr. Mark Freedman to Join Opexa’s Scientific Advisory Board

Arcos, Inc. adds Chief Medical Officer
Release Date: 31-Aug-11 Author or Contact: Chris Meador Category: Recent News
HOUSTON, Aug 30, 2011 -- Arcos, Inc. announced today that Stephan Wexler, MD, MBA, JD has joined Arcos as its Chief Medical Officer. Dr. Wexler has 20 years experience in plastic surgery and is familiar with many aspects of sepsis, burn, and trauma critical care. "We are delighted to have Dr. Wexler join Arcos," said Chris Meador, CEO of Arcos. "In addition to providing important 'voice of the ...
Click to read Arcos, Inc. adds Chief Medical Officer

Contact Us | Site Map |

| OPML | Search This Site | Home
Schipul Web Design | Houston Social Media | Tendenci® Content Management Software | Privacy | Terms and Conditions